ReviewObesity (Silver Spring, Md.)2026
The Effects of Incretin Mimetic Therapies on Muscle and Bone Health in Older Adults: A Narrative Review.
Review in Obesity (Silver Spring, Md.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Incretin mimetics are increasingly prescribed for the treatment of overweight and obesity, resulting not only in significant weight reduction but also co-occurring improvements in cardiovascular health and quality of life. Incretin mimetic use among older adults is expected to increase as the population ages into obesity. However, older adults experience accelerated losses in skeletal muscle mass and bone mineral density, and it remains unclear how incretin mimetics affect these processes. This review outlines the age-associated changes in muscle and bone and explores current evidence reporting the effects/associations of incretin mimetics on these tissues, as well as on physical function and fragility fracture risk. We identified several incretin mimetic weight reduction trials that demonstrated significant losses in lean soft tissue (n = 6 studies) and/or indices of bone (n = 3); however, the clinical significance of these decrements on physical function and/or fragility fracture remains unclear. Considering a rising trend in the prescription of incretin mimetics to treat obesity in older adulthood, a more robust characterization of the impact of these medications on lean soft tissue, physical function, and fragility fracture is needed to support future clinical decision-making in older adults with overweight/obesity.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.